Exploration of clinical complete remission and adverse events of vedotinumab combined with PD-1 inhibitors in neoadjuvant therapy of bladder cancer
10.3969/j.issn.1009-8291.2025.10.002
- VernacularTitle:维迪西妥单抗联合程序性死亡受体1抑制剂用于膀胱癌新辅助治疗的疗效与不良反应探索
- Author:
Yifan WANG
1
;
Mingshuai WANG
1
;
Yajian LI
1
;
Gang SONG
1
;
Yong ZHANG
1
Author Information
1. 国家癌症中心,国家肿瘤临床医学研究中心,中国医学科学院北京协和医学院肿瘤医院泌尿外科,北京 100021
- Publication Type:Journal Article
- Keywords:
neoadjuvant chemotherapy;
programmed cell death 1 inhibitors;
muscle-invasive bladder cancer;
vedotinumab;
toripalimab;
gemcitabine;
cisplatin
- From:
Journal of Modern Urology
2025;30(10):824-827
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and adverse events of antibody-drug conjugate(ADC)combined with PD-1 inhibitors in neoadjuvant therapy for muscle-invasive bladder cancer.Methods A retrospective study included 22 patients with bladder cancer who received neoadjuvant therapy with ADC combined with PD-1 inhibitors and gemcitabine+cisplatin(GC)regimen combined with PD-1 inhibitors in the Department of Urology,Cancer Hospital,Chinese Academy of Medical Sciences from Nov.2020 to Jan.2025.The patients were divided into the vedotinumab combined with toripalimab group and the GC combined with toripalimab group.The clinical complete response rate(cCR)of the two groups of patients was compared and analyzed,and the adverse events(AEs)that occurred during the medication period were evaluated simultaneously.Results The cCR in the vedotinmab combined with toripalimab group was higher than that in the GC combined with toripalimab group(54.5％vs.27.3％),but the difference was not statistically significant(P=0.387).In the vedotinumab combined with toripalimab group,one patient(9.1％)developed grade 3-4 AEs,presenting with peripheral sensory nerve function decline,nausea,loss of appetite and fatigue.Two patients(18.2％)in the GC combined with toripalimab group developed grade 3-4 AEs,presenting with leukopenia and nausea.Conclusion In neoadjuvant therapy for bladder cancer,ADC(vedotinumab)combined with PD-1 inhibitors(toripalimab)has better clinical complete remission and adverse events compared with the traditional GC combined with PD-1 inhibitors regimen.
